Hussain T, Tan B, Yin Y, Blachier F, Tossou MCB, Rahu N
The FDA has stated that compounded BPC-157 may present immunogenicity and peptide-characterization risks and that available safety information is insufficient to determine whether proposed uses could harm humans
Composition BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of BPC-157 and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of two co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Diet and specific nutrients Omega-3 fatty acids, particularly DHA, support BDNF expression through their role in neuronal membrane composition and anti-inflammatory signaling
